Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50p -0.95% 156.50p 153.00p 160.00p 159.00p 156.50p 158.00p 25,085 11:03:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 17.1 2.6 5.0 31.2 66.19

Tristel (TSTL) Latest News

More Tristel News
Tristel Takeover Rumours

Tristel (TSTL) Share Charts

1 Year Tristel Chart

1 Year Tristel Chart

1 Month Tristel Chart

1 Month Tristel Chart

Intraday Tristel Chart

Intraday Tristel Chart

Tristel (TSTL) Discussions and Chat

Tristel Forums and Chat

Date Time Title Posts
20/10/201615:31The TRISTEL story2,138
15/7/201513:01Tristel PLC: Cleaning up the sector340
03/1/201004:54tristel with charts-
14/3/200612:13MRSA cleaner246
13/2/200607:10TSTL with Charts & News3

Add a New Thread

Tristel (TSTL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Tristel trades in real-time

Tristel (TSTL) Top Chat Posts

Tristel Daily Update: Tristel Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 158p.
Tristel Plc has a 4 week average price of 156.53p and a 12 week average price of 141.48p.
The 1 year high share price is 165p while the 1 year low share price is currently 88.50p.
There are currently 42,293,701 shares in issue and the average daily traded volume is 102,620 shares. The market capitalisation of Tristel Plc is £66,189,642.07.
rcturner2: A PE of 20 is not expensive for a company that is growing this fast. The US entry is a bonus that is not priced into the share price, in my opinion.
duncan doughnut: Nice to see the constant share price rise here recently. I had my doubts when there was the director selling recently but still moving up nicely.
rcturner2: Good statement today about the approval in Australia of a new product. Nice rise in the share price against the overall market direction.
james188: Just a couple of points I picked up in discussions after the main meeting, to add to the very helpful summary provided by Glaws2 above. 1. We have yet to see a breakdown in relation to the strong H2 overseas growth, but I understand that it was reasonably evenly distributed and not due to a spike in one jurisdiction. That said, Germany was mentioned as a strong performer. 2. At the time of the December 2015 AGM, Equity Development produced a very bullish note. Amongst other things,that note referred to Tristel having come up with a "major breakthrough in household cleaners" incorporating chlorine dioxide. I think that there was some cynicism at the time - i.e. that that was hype to drive up the share price. It is certainly true that it is very early days. However, Tristel now have a working name for the product - Puffin - and have designed a prototype container/screwcap containing the Clo2 capsules, which was on display yesterday as one of the new products that is being actively developed. A fairly low cost initiative, but it will be interesting to see if it comes to anything. More generally, I was pleased to see that Tristel continue to be active in developing a range of new offerings.
source: By Equity Development:- "...In the US the process of seeking product authorisation from the FDA and EPA carries on at pace, and is on track to (hopefully) obtain approval in 12 months' time. We have duly upgraded our FY17 turnover and PBTA forecasts by +9% and +7%, to £19.5m and £3.54m respectively. Likewise, our fair value share price target climbs 8% to 135p."
apad: It's all about the US. If you succeed there it's not like anywhere else. The CEO (say it quietly in case Piedro is listening) says that selling into the NHS is the worst that there ever was (Talking Heads). Whatever happens to the share price under tiddly little PI buying and selling is as of nothing. Iff there is any news they will be holding it back for the "investor day". It's exciting if nothing else :-) apad
nehpets81: I don't think he would be buying little chunks in dribs and drabs if he was intending to take the company private as his actions (plus the orchestrated director buying we saw a few days ago) has the effect of boosting the share price. He either sees the shares as cheap or he is trying to create a floor for the share price, I suspect a bit of both.
source: Another update from Paul Scott (turning more positive)... Regards, Source. +++++++++++++ Tristel (LON:TSTL) Share price: 108.75p (up 4.6% today) No. shares: 42.2m Market cap: £45.9m (at the time of writing, I hold a long position in this share) Director purchases - I'm really not a fan of orchestrated Director share purchases after bad news, but as mentioned recently for another company, it does seem to work in some situations anyway, in helping to reassure investors. Perhaps it works in marginal situations, where confidence is beginning to return anyway, which is how I see Tristel? I reported here on 24 Feb 2016 on Tristel's interim results, and the various factors which triggered a sharp correction in the share price. My view, when the shares were at 125p at the time of writing that report, was that the price looked "a bit too high", but that the "longer term upside still looks good". The share price subsequently dropped considerably more, and went as low as the low-mid 90p's yesterday morning. At around that level, I think it was a reasonably good purchase, so I picked up a few, more of a dabble than a conviction buy. Management webinar - I was also really impressed with the webinar that TSTL management did with Equity Development yesterday lunchtime. I watched/listened, and felt that management were open in addressing the criticisms of the slowing sales growth, and the share options charge. There's no doubt they have dropped a big clanger with a badly designed share options scheme, but I think they recognise that, and were emphatic that there would be no repetition in the next 3-5 years. Various other factors mitigate my concerns over the slowing growth rate (now 8%), such as 4% being due to currency effects, and also that low margin products have been dropped - hitting turnover, but having little to no impact on profit. Overall, I take my hat off to TSTL management for being so open with private investors, and not only holding a webinar, but also a meeting in London, open to private investors. Feedback from this has also been positive. This is outstanding stuff - if only all companies were so willing to engage with their PI shareholder base - especially when contentious issues arise. TSTL is already being rewarded with a rebound in the share price. I think the glass is slowly turning from half empty, to half full again. The upside from potential US FDA approvals is something that I'd like to stick around for, as that could be a significant catalyst for future growth. I'm not sure there is necessarily much short term upside from here, but who knows? I would have thought it might recover to say 120-130p after a while.
apad: Great start to the Beddard article: "Tristel’s share price has dived because it’s not doing as well as managers led credulous investors to believe it would. That isn’t to say it’s doing badly. Maybe it was the harsh office lighting, maybe it was the gruelling two-day schedule of schmoozing in the City, but my first impression when tuning into Tristel’s interim results webcast on Thursday was that chief executive Paul Swinney and finance director Liz Dixon could do with a good night’s sleep. Maybe the near 35% drop in the share price on Wednesday kept them awake." I felt credulous and thought they looked knackered. apad
tmfmayn: Effortless -- "There may be a reversal of part of this cost if the share price stays below 134p - anyone know?" I am not an expert on option accounting, but I would guess that a reversal of this charge would depend on a specific provision in the option documentation that could negate the options' original vesting condition. I very much doubt there is such a provision, but we can live in hope. A reversal could also occur (I think) if the directors were to forfeit their options for some reason. The charge assumes the directors will still be around to collect these options. Any reversal would be accounted for in the relevant future period as a credit to the income statement, and the amount charged in these latest results would not be restated. It seems to me that your £848k sum is in the right ball park (perhaps there are other senior managers with the same options, to get the charge to £1m) and that TSTL has decided to charge the majority of these '30-day/134p' options during this H1 period. The original announcement cited these options would vest in October this year, and become available over three years. Perhaps management expected the charge to be expensed over a few years, not just 6 months. I should add that nobody here was complaining when the shares topped 134p for 30 days during December/January -- and yet that option grant had been known since August. I guess if a company grants options dependent on share-price performance, we have to accept there will be a P&L cost when the share price goes up! It will be interesting to see when senior management receive its next batch of options, and what the associated vesting conditions are.
Tristel share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20161021 13:13:03